HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
PHAR
Pharming Group N.V.
There isn't enough reported data to score PHAR yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
PHAR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Strong |
PHAR's balance sheet is currently strong, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
PHAR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 17x | N/A | N/A |
| Fair | 35x | N/A | N/A |
| Expensive | 280x | N/A | N/A |
| Current | 324x | $12.95 | — |
Historical ranges are pointers, not guarantees.
PHAR's PE is 324x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
PHAR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect PHAR's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
PHAR has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus PHAR down 100%.
PHAR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.00 | +$0.02 |
| Q4 2024 | -$0.02 | $0.00 |
| Q4 2023 | -$0.02 | -200% |
| Q4 2022 | $0.02 | 0% |
| Q4 2021 | $0.02 | -60% |
| Q4 2020 | $0.05 | -90% |
| Q4 2019 | $0.51 | +27% |
| Q3 2019 | $0.54 | +$1.17 |
PHAR has swung to a loss: it lost $0.00 per share over the past year, after a profit the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
PHAR has the stronger quarterly revenue trend. Revenue is up 49% for HIMS versus up 89% for PHAR.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
PHAR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $376.1M | +27% |
| Q4 2024 | $297.2M | +21% |
| Q4 2023 | $245.3M | +19% |
| Q4 2022 | $205.6M | +3.4% |
| Q4 2021 | $198.9M | -3.6% |
| Q4 2020 | $206.3M | +242% |
| Q4 2019 | $60.4M | +35% |
| Q3 2019 | $51.5M | +2% |
PHAR's revenue has grown year over year for 10 quarters in a row: $376M last quarter, up 89% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 6.9% | 0 points |
| Q4 2024 | -2.9% | -39 points |
| Q4 2023 | -2.2% | -42 points |
| Q4 2022 | 8.9% | -32 points |
| Q4 2021 | 6.8% | -22 points |
| Q4 2020 | 36% | +1.2 points |
| Q4 2019 | 40% | +21 points |
| Q3 2019 | 40% | +2.5 points |
PHAR's operating margin was 6.9% last quarter, about level with the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
PHAR has the stronger cash trend. Its trailing FCF is down 9.5% versus its history, compared with HIMS at down 84%.
PHAR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $54M | +$56.5M |
| Q4 2024 | -$2.6M | +$16.2M |
| Q4 2023 | -$18.7M | -189% |
| Q4 2022 | $21.1M | -22% |
| Q4 2021 | $27.1M | -65% |
| Q4 2020 | $77.6M | +257% |
| Q4 2019 | $21.7M | +21% |
| Q3 2019 | $3.4M | -82% |
PHAR generated $54M in free cash flow over the past year, down 59% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over PHAR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
PHAR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.9% | -38.5M shares |
| 1 year | +6.5% | +45.7M shares |
| 3 years | +978% | +678M shares |
| 5 years | +1302% | +694M shares |
PHAR has 747M diluted shares, up 6.5% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
| Q3 2019 | — |
| Q2 2019 | — |
| Q1 2019 | — |
| Q4 2018 | — |
| Q3 2018 | — |
| Q2 2018 | — |
| Q1 2018 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
PHAR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2019 | -0.2x | Net Cash |
| Q3 2019 | -0.2x | Net Cash |
| Q2 2019 | 0.1x | Very low |
| Q1 2019 | -0.1x | Net Cash |
| Q4 2018 | 0.1x | Very low |
| Q3 2017 | 4.2x | High |
PHAR has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
PHAR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 79.2 | Neutral |
PHAR's weekly RSI is 55 (neutral) and its Stochastic is 79 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
PHAR PE vs Healthcare Sector
| Metric | PHAR | Sector median | Relative |
|---|---|---|---|
| PE | 324x | 26x | 1,152% above |
| PE % | 93 | 34 | 59 pts above |
PHAR is trading at 324x earnings, a 1152% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
PHAR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.0 | 18% above |
| 20 week MA | $11.6 | 12% above |
| 50 week MA | $14.2 | 8.5% below |
| 100 week MA | $12.7 | 1.8% above |
| 200 week MA | $11.7 | 11% above |
PHAR has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
PHAR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.6 | $15.6 | 0% |
| 2021 | $15.6 | $8.75 | -44% |
| 2022 | $8.75 | $11.8 | +34% |
| 2023 | $11.8 | $11.4 | -2.7% |
| 2024 | $11.4 | $10.2 | -11% |
| 2025 | $10.2 | $17.8 | +74% |
| 2026 YTD | $17.8 | $13.0 | -27% |
PHAR has the edge over HIMS on returns for 2026, with the stronger performance.